| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Nanomedicine | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Nanomedicine | Oncology | ||
Phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Nanomedicine | Oncology |
Recent Updates
Recently added Catalysts
GT Biopharma, Inc.$0.29
-0.01 (-4.65%)
D 26Pipeline Score Richly Valued Pharma · Clinical
Market Cap
15.87 M
EPS
-14.40
P/E Ratio
-
Value Trade
427.79 K
-2.4 %
Week
21.55 %
1 Month
-6.38 %
3 Month
-38.72 %
6 Month
-99.9 %
5 Year
-100 %
All Time
Cash Data
Cash Position
8.92 M
Monthly Burn
823.00 K
Runway
8.4 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
602.21 K
52 Week Range
0.26 - 3.85
% held by Insiders
5.51 %
% held by Institutions
6.1 %
Enterprise Value
6.85 M
Total Shares
31.55 M
Short %
16.22 %
Float Shares
29.50 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for GT Biopharma, Inc.
87Total events
4Upcoming
11Tier-1 (high impact)
2004 – 2027Coverage
Upcoming catalysts 2
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutGTB-3650Clinical Data
Subscribe to view catalyst details
TBD
◆Timing GuidanceGTB-5550Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-01-31 | GTB-5550 TriKE® | IND Filing | IND | — | – | – | – |
2026-01-31 | GTB-5550 TriKE® | IND Filing | IND | — | – | – | – |
2026-01-31 | GTB-5550 TriKE® | IND Filing | IND | — | – | – | – |
Drug Pipeline Intelligence
D26
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 28%
Micro Cap (rank 658 of 913)
Percentile RankGT Biopharma, Inc. faces pipeline headwinds (26/100), with $231M risk-adjusted pipeline value, led by GTB-5550 in Tri-specific Killer Engager (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GTB-5550 Small molecule | Tri-specific Killer Engager | Phase 1 | NCT07541573 | 5% | $190M | RECRUITING | 175 | - | - | Jan 1, 2032 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GTBP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GTBP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GTBPA Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
GT Biopharma, Inc. is leveraging AI-based tools in the discovery and engineering of its tumor-targeting therapies, aiming to accelerate development and reduce costs. The company anticipates advancing multiple new candidates into pre-IND development by 2027. Their existing clinical programs, GTB-3650 and GTB-5550, are currently in Phase 1 trials. The success of this AI initiative will depend on the performance of the candidates it generates.
Read more →GTBP▲ +11.3%on this newsshared move
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
GT Biopharma, Inc. is leveraging AI tools to enhance its drug discovery process, aiming to accelerate the development of multiple new candidates expected to enter pre-IND development by 2027. The company is currently advancing two clinical programs, GTB-3650 and GTB-5550, through Phase 1 trials. While the AI approach shows promise, significant risks remain, including financial constraints and the uncertainty of clinical outcomes.
Read more →GTBP▲ +5.7%on this news
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
GT Biopharma, Inc. has commenced a Phase 1 trial for its third drug, GTB-5550, targeting solid tumors. This milestone highlights the company's unique TriKE platform, which now has three candidates in human trials. However, the company faces challenges, including a limited cash runway and the inherent risks associated with early-stage oncology trials.
Read more →GTBP▼ -7.6%on this newsshared move
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
GT Biopharma has announced advancements in its pipeline due to the implementation of AI-based technologies. These initiatives are expected to enhance the discovery and development of tumor-targeting engagers and multi-domain proteins, potentially leading to new candidates entering pre-IND development by 2027. The company aims to improve clinical success rates while reducing costs and timelines.
Read more →GTBP▲ +7.4%on this newsshared move
The $13 Million Company Teaching the Immune System to Hunt Cancer
GT Biopharma, a clinical-stage immuno-oncology company with a market cap of $13 million, is advancing three drug candidates in human trials. Their unique TriKE platform aims to enhance the immune system's natural killer cells to target tumors. Despite significant potential in a growing oncology market, the company faces challenges, including lack of approved products and limited cash reserves.
Read more →GTBP▲ +18%on this news
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
GT Biopharma has initiated clinical trials for three TriKE candidates targeting various cancers. The first patient was dosed in the GTB-5550 Phase 1 trial, which utilizes a novel subcutaneous dosing method. The 2nd-generation TriKE platform is reported to be significantly more potent than its predecessor, aiming to improve treatment outcomes for patients with specific malignancies.
Read more →GTBPGT Biopharma Reports Full Year 2025 Financial Results
GT Biopharma reported its financial results for 2025, highlighting ongoing Phase 1 trials for GTB-3650 and GTB-5550. The company anticipates significant milestones in 2026, including the initiation of the GTB-5550 trial. Despite a net loss of $28.4 million, GT Biopharma maintains a strong cash position to support its operations through Q4 2026.
Read more →GTBPGT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GT Biopharma, Inc. will participate in the Centurion One Capital 9th Annual Toronto Growth Conference on March 5, 2026. Michael Breen, the Executive Chairman and CEO, will present and engage in panel discussions, along with one-on-one investor meetings. The company focuses on developing immuno-oncology therapeutics using its proprietary TriKE platform.
Read more →GTBPGT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
GT Biopharma has received FDA clearance for its IND application for GTB-5550, a TriKE® targeting B7-H3 in solid tumors. The Phase 1 trial is set to begin in mid-2026, focusing on advanced prostate, ovarian, and pancreatic cancers. The trial will assess safety, tolerability, and preliminary anti-tumor activity across multiple solid tumor types. This development is seen as a pivotal step in advancing immunotherapy for patients with limited treatment options.
Read more →GTBPFunctional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
GT Biopharma, Inc. has submitted an investigational new drug application for GTB-5550, a B7-H3-targeted NK cell engager aimed at treating solid tumors. This submission is part of a broader trend in precision medicine, shifting towards platform-based biologics. The company is also advancing its Phase 1 trial for GTB-3650, targeting blood cancers. Both therapies leverage GT Biopharma's proprietary TriKE platform.
Read more →GTBP▲ +10.6%on this newsshared move
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GT Biopharma has submitted an IND application for GTB-5550, a novel NK cell engager targeting B7-H3 solid tumors. The company plans to initiate a Phase 1 trial in 2026, building on insights from its ongoing GTB-3650 trial in myeloid blood cancer. The trial aims to explore safety and efficacy across multiple solid tumor types.
Read more →GTBP▲ +26.1%on this news
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update Phase 1 trial evaluating GTB-3650 TriKE for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to activ
GT Biopharma, Inc. reported its financial results for Q3 2025 and provided an update on its clinical trials. The ongoing Phase 1 trial for GTB-3650, aimed at treating relapsed or refractory CD33 expressing hematologic malignancies, continues to recruit patients, with results expected in Q1 2026. The company plans to submit an IND application for its conditionally promising GTB-5550 by early 2026. Despite a net loss reported for the quarter, the company remains optimistic about its clinical advances and has enough cash to sustain operations into the next year.
Read more →GTBP▲ +9%on this news
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
GT Biopharma has successfully completed the safety review for Cohort 3 of its Phase 1 trial for GTB-3650, allowing progression to Cohort 4. The trial will evaluate the drug's efficacy in patients with relapsed or refractory CD33 expressing hematologic malignancies. The next update is anticipated in Q1 2026, with potential for further dose escalation.
Read more →GTBP▲ +10.6%on this news
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GT Biopharma, Inc. will participate in the Centurion One Capital 3rd Annual Bahamas Summit on October 28-29, 2025. Michael Breen, the Executive Chairman and CEO, will represent the company at the event, which will include opportunities for one-on-one meetings. This participation highlights GT Biopharma's focus on immuno-oncology and its proprietary TriKE® platform.
Read more →GTBPGT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GT Biopharma is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The company is progressing with its Phase 1 trial for GTBP-3650 and plans to submit an IND for GTB-5550 TriKE® by Q4 2025. Investors can schedule one-on-one meetings during the conference.
Read more →GTBP▼ -7.6%on this news· ran to -26% by day 3
GT Biopharma Reports Second Quarter 2025 Financial Results
GT Biopharma reported its second quarter 2025 financial results, highlighting strong enrollment in its Phase 1 trial for GTB-3650. The trial is progressing well, with a successful safety review and early signs of immunological activity. Financially, the company has reduced R&D and SG&A expenses, but reported a net loss of $1.4 million.
Read more →GTBPGT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2
GT Biopharma has advanced to Cohort 3 of its Phase 1 trial for GTB-3650 after a successful safety review of Cohort 2. The trial evaluates GTB-3650 for relapsed or refractory CD33 expressing hematologic malignancies. Initial results from earlier cohorts show promising immune activity, with plans to release more data in 2025.
Read more →GTBPGT Biopharma Appoints New Member to its Board of Directors
GT Biopharma has appointed David C. Mun-Gavin to its Board of Directors. Mun-Gavin brings extensive executive experience from global financial institutions and will provide valuable guidance as the company approaches its first data readout for GTBP-3650. This appointment aligns with GT Biopharma's strategy to expand its NK-engager pipeline in the coming years.
Read more →GTBPGT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
GT Biopharma has successfully completed Cohort 1 of its Phase 1 trial for GTB-3650, with no safety issues reported. The trial is evaluating the drug's effectiveness in treating relapsed or refractory CD33 expressing hematologic malignancies. Following positive results, the company has initiated dosing in Cohort 2 and plans to release more detailed results in 2025.
Read more →GTBP▼ -15.7%on this news
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies Initial data from the Phase 1 trial expected in 2025
GT Biopharma has announced the dosing of the first patient in its Phase 1 trial of GTB-3650, a second-generation TriKE aimed at treating relapsed or refractory CD33 expressing hematologic malignancies. This marks a significant milestone for the company as it evaluates GTB-3650's safety and efficacy in a small patient cohort. Initial data from the study is anticipated in 2025, which will shed light on the drug's potential effectiveness. The trial involves a two-week dosing regimen and aims to assess various parameters, including pharmacokinetics and clinical activity.
Read more →GTBP▼ -7.1%on this news
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical
GT Biopharma has received FDA clearance for its Investigational New Drug application for GTB-3650, a NK cell engager aimed at treating CD33+ leukemia. The Phase 1 trial for GTB-3650 is expected to begin in the second half of 2024, with initial clinical data anticipated in the first half of 2025. Alongside this development, GT Biopharma plans to submit an IND for GTB-5550, targeting B7H3 positive solid tumors, scheduled for Q1 2025 with a Phase 1 trial starting thereafter. The company also assures that its financial resources will support its operations through 2025.
Read more →GTBP▼ -28.2%on this news· ran to -53% by day 3
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules BRISBANE, CALIFORNIA
GT Biopharma, Inc. announced a registered direct offering priced at-the-market of 740,000 shares at $4.35 each, expected to generate approximately $3.2 million in gross proceeds. The closing is anticipated around May 23, 2024, subject to customary conditions. Concurrently, the company will issue warrants for the same number of shares. The proceeds are intended for general corporate purposes, enhancing the company's financial capacity for its immuno-oncology projects.
Read more →GTBP▼ -6.2%on this news· ran to -18% by day 3
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split BRISBANE, CALIFORNIA
GT Biopharma, Inc. announced a 1-for-30 reverse stock split to comply with Nasdaq's Minimum Bid Price Requirement. The split will reduce the outstanding shares significantly from approximately 41 million to about 1.4 million. Stockholders' shares will be adjusted automatically in brokerage accounts, while certificate holders will receive instructions for the exchange. This measure was approved by stockholders in December 2023 and aims to stabilize the company's stock price on the Nasdaq Capital Market.
Read more →GTBPGT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia BRISBANE, CALIFORNIA
GT Biopharma has announced the submission of an Investigational New Drug (IND) application for GTB-3650, a therapeutical agent targeting CD33+ leukemia. The drug is particularly aimed at patients with relapsed or refractory acute myelogenous leukemia and high-risk myelodysplastic syndrome. This IND submission represents a significant step forward for the company as it prepares to enter the clinical trial phase in 2024. Executives have expressed optimism about the therapeutic potential of the new drug.
Read more →GTBPGT Biopharma Names Charles J. Casamento to the Board of Directors BRISBANE, CALIFORNIA
GT Biopharma, Inc. appointed Charles J. Casamento to the Board of Directors, effective May 1, 2023, filling a vacancy left by Alan Urban's resignation. Casamento, with over 35 years of experience in the biopharma sector, will serve on several board committees including Audit, Compensation, and Nominating and Corporate Governance. The company aims to leverage his extensive background to further its pipeline development as it transitions into a clinical stage immuno-oncology firm.
Read more →GTBP▼ -8.7%on this news
GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market BRISBANE, CALIFORNIA
Biopharma, Inc. Announces $6.5 Million Registered Direct Offering At Premium To Market CALIFORNIA, December 30, 2022 (GLOBE NEWSWIRE) - GT Biopharma, Inc. (the "Company" or "GTB") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therape
Read more →GTBPGT Biopharma Announces Adjournment of Special Shareholders Meeting - Meeting adjourned to
Biopharma Announces Adjournment of Special Shareholders Meeting - Meeting adjourned to October 10, 2022 at 11 a.m. PST - GTB encourages all stockholders of record on August 8, 2022 who have not yet voted - to do so by 11:59 p.m. PST Time on October 9, 2022 CALIFORNIA, October
Read more →GTBPGT BIOPHARMA ANNOUNCES EXPANDED TRiKE PARTNERSHIP WITH CYTOVANCE BIOLOGICS Sign $6,000,000.00 Agreement
GT BIOPHARMA ANNOUNCES EXPANDED TRiKE PARTNERSHIP WITH CYTOVANCE Sign $6,000,000.00 Agreement BEVERLY HILLS, CALIFORNIA, October 6, 2020 / Accesswire / -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on it
Read more →GTBPGT BIOPHARMA ANNOUNCES THE SALE OF ITS FIXED DOSE COMBINATION TABLET (GTB-004) FOR MYASTHENIA GRAVIS (CHRONIC AUTOIMMUNE DISEASE)
GT BIOPHARMA ANNOUNCES THE SALE OF ITS FIXED DOSE COMBINATION TABLET (GTB-004) FOR MYASTHENIA GRAVIS (CHRONIC AUTOIMMUNE DISEASE) Florida, September 24, 2019 / PRNewswire / -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatmen
Read more →GTBPGT Biopharma Reports Third Quarter 2018 Financial Results and Provides Business Update – Recent corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational 2019
GT Biopharma Reports Third Quarter 2018 Financial Results and Provides Business Update Recent corporate, preclinical, clinical and regulatory advancements expected to position Company for a transformational FDA clearance of IND to advance first-in-class TriKE, GTB-3550, into
Read more →GTBPGT BIOPHARMA ANNOUNCES DR. RAYMOND W
GT BIOPHARMA ANNOUNCES DR. RAYMOND W URBANSKI ELEVATED TO PRESIDENT AND CHIEF MEDICAL OFFICER OF THE COMPANY ANGELES, CA, May 14, 2018 - GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA") today announced the promotion of Dr. Raymond W Urbanski MD, PhD to the positio
Read more →GTBPFormer Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors
Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors ANGELES, April 24, 2018 /PRNewswire/ -- Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA") today announced that Dr. Peter Kiener will join GT Biopharma's Board of Direct
Read more →GTBPGT Biopharma (GTBP: OTCQB) Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer WASHINGTON, DC / ACCESSWIRE /
GT Biopharma (GTBP: OTCQB) Announces Appointment of Shawn M Cross as Chairman and Chief Executive Officer WASHINGTON, DC / ACCESSWIRE / February 15, 2018 / GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) ("GT" or the "Company"), a clinical-stage biopharmaceutical company focused
Read more →GTBPGT Biopharma Announces $7.1 Million Convertible Debt Financing
GT Biopharma Announces $7.1 Million Convertible Debt ANGELES, CA, January 23, 2018 - GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA") today announced that it has entered into definitive agreements for a private placement of convertible notes and warrants for gross
Read more →GTBPGEOFFREY B. DAVIS JOINS GT BIOPHARMA'S
GEOFFREY B. DAVIS JOINS GT BIOPHARMA'S BOARD OF ANGELES, CA, January 16, 2018 - GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA") today announced that Geoffrey B. Davis will join GT Biopharma's Board of Directors effective immediately. Mr. Davis is the founding par
Read more →GTBPGT Biopharma, Inc. announces Shawn M. Cross, 20-Year Healthcare Investment Banking Industry Veteran, as President and Chief Operating Officer. Washington, DC / Accesswire /
GT Biopharma, Inc. announces Shawn M. Cross, 20-Year Healthcare Investment Banking Industry Veteran, as President and Chief Operating Washington, DC / Accesswire / November 16, 2017 GT Biopharma, Inc. (GTBP) (GTBP.PA) ( GT or the Company ), a clinical-stage biopharmaceutical
Read more →GTBPGT BIOPHARMA ANNOUNCES STOCK SALES AGREEMENT WITH HOLDERS OF CONVERTED SECURITIES WASHINGTON D.C., CA / ACCESSWIRE / OCTOBER 12, 2017 / GT Biopharma Inc. (GTBP and Euronext Paris GTBP.PA) announced today that persons who
GT BIOPHARMA ANNOUNCES STOCK SALES AGREEMENT WITH HOLDERS WASHINGTON D.C., CA / ACCESSWIRE / OCTOBER 12, 2017 / GT Biopharma Inc. (GTBP and Euronext Paris GTBP.PA) announced today that persons who received common stock ( Common Stock ) upon the conversion of notes, preferred
Read more →GTBPOXIS International Reports October Revenues Match Total 3 rd Quarter Revenues.
OXIS International Reports October Revenues Match Total 3rd Quarter Revenues. BEVERLY HILLS, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- via PRWEB - OXIS International, Inc., (OXIS) (OXI.PA) today announced revenues for October were in excess of $105,000. This represents a threefol
Read more →GTBPOXIS International Announces Significant Revenues During the 3rd Quarter From the Launch of Its Skin Care Product Line
OXIS International Announces Significant Revenues During the 3rd Quarter From the Launch of Its Skin Care Product Line BEVERLY HILLS, Calif., Oct. 24, 2012 (GLOBE NEWSWIRE) -- via PRWEB - OXIS International, Inc., (OXIS) (OXI.PA) today announced revenues for the third quarter we
Read more →GTBPOXIS International Forms Joint Venture to Develop Ergothioneine-Based Treatment for Acute Lung Injury Initial Research Funding to Come From U.S. Department of Defense Grant BEVERLY HILLS, Calif. (
OXIS International Forms Joint Venture to Develop Ergothioneine-Based Treatment for Acute Lung Injury Initial Research Funding to Come From U.S. Department of Defense Grant BEVERLY HILLS, Calif. (July 11, 2011) - OXIS International, Inc. (OTC/BB: OXIS; Euronext Paris: OXI) tod
Read more →GTBPOXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors
OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors BEVERLY HILLS, Calif., June 27, 2011 - OXIS International, Inc. (OTC Bulletin Board: OXIS; Euronext Paris: OXI) today announced that it has named former Wal-Mart executive Ken Eaton to its Board
Read more →GTBPLETTERHEAD OF OXIS INTERNATIONAL, INC.] Oxis International, Inc. Announces the Appointment of Bernie Landes as President Previous Experience Includes Positions as Former Health Valley Foods Executive and Current Presiden
[LETTERHEAD OF OXIS INTERNATIONAL, INC.] Oxis International, Inc. Announces the Appointment of Bernie Landes as President Previous Experience Includes Positions as Former Health Valley Foods Executive and Current President of Monavie's Scientific Advisory Board - Press Release
Read more →GTBPASSIGNMENT AND ASSUMPTION AGREEMENT This Assignment and Assumption Agreement (this " Agreement ") is made as of
AND ASSUMPTION AGREEMENT Assignment and Assumption Agreement (this "Agreement") is made as of April 7, 2009, by and among BRISTOL INVESTMENT FUND, LTD., a _________ company ("Assignee"), INTERNATIONAL, INC., a Delaware corporation ("Assignor"). WHEREAS, in connection with a
Read more →GTBPOXIS International, Inc. 323 Vintage Park Drive, Suite B, Foster City, California 94404
OXIS International, Inc. Vintage Park Drive, Suite B, Foster City, Investment Fund, Ltd. Capital Fund Limited of our Board of Directors and in the best interests of our shareholders, debt holders, employees, customers and suppliers, I am requesting that each of you move imm
Read more →GTBPUnassociated Document
Unassociated Document
Read more →GTBPOXIS INTERNATIONAL, INC. 2003 STOCK INCENTIVE PLAN NOTICE OF STOCK OPTION AWARD Optionee's Name and Address: Matthew Spolar 81 71 st Street Brooklyn, NY 11209 You (the "Optionee") have been granted an option to purchase
INTERNATIONAL, INC. 2003 STOCK INCENTIVE PLAN OF STOCK OPTION AWARD Optionee's Name and Address: Matthew Spolar 81 71 st Street Brooklyn, NY 11209 "Optionee") have been granted an option to purchase Common Shares, subject to the terms and conditions of this Notice of Stock
Read more →GTBPOXIS International Reports Financial Results for First Quarter 2006 Product Revenues Increase 140% over 2005 New Cardiac and Cancer Research Products and Value Pricing to Drive Sales Volume Results Include 51% Ownership
International Reports Financial Results for First Quarter Revenues Increase 140% over 2005 Cardiac and Cancer Research Products and Value Pricing to Drive Sales Volume Include 51% Ownership in BioCheck, Inc. Beginning in December City, CA (May 9, 2006) - Oxis International, I
Read more →GTBPGary Post, Managing Director and Investment Principal of Ambient Advisors, LLC, Joins OXIS' Board of Directors Company Strengthens Short-Term Financial Position with Line of Credit from President and CEO Steve Guillen Fo
Post, Managing Director and Investment Principal of Ambient Advisors, LLC, OXIS' Board of Directors Strengthens Short-Term Financial Position with Line of Credit from President City, CA - March 21, 2006 - OXIS International (OTCBB: OXIS.OB) (Nouveau March : OXIS) (FWB: OXI),
Read more →GTBPSTOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this Agreement ) is made as of
STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this Agreement ) is made as of September 19, 2005, by and between OXIS International, Inc., a Delaware corporation (the Buyer ), Bio Check, Inc., a California corporation (the Company ) and holders of capital stock of the
Read more →GTBPEXECUTION COPY OXIS INTERNATIONAL, INC. CONVERSION AGREEMENT THIS CONVERSION AGREEMENT (this Agreement ) is entered into as of
OXIS INTERNATIONAL, INC. CONVERSION AGREEMENT THIS CONVERSION AGREEMENT (this Agreement ) is entered into as of May 23, 2005 by and between OXIS International, Inc., a Delaware corporation (the Company ), and Equitis Entreprise, a French soci t par actions simplifi e ( Equitis
Read more →GTBPWill Anderson Obidicut LLC (503) 452-7621 will@obidicut.net
OXIS INTERNATIONAL APPOINTS STEVE PRESIDENT AND CHIEF EXECUTIVE OFFICER PORTLAND, Ore. February 28, 2005 OXIS International, Inc. (OTCBB: OXIS) (Nouveau March : OXIS), a leader in the evaluation and treatment of diseases associated with oxidative stress, announced today the ap
Read more →GTBPSECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this Agreement ) is dated as of December 30, 2004, among Oxis International, Inc., a Delaware corporation (the Company ), and each purchaser identified on the signature pages hereto (each, including its successor
Read more →GTBPMarvin S. Hausman MD Rejoins OXIS International Inc. Board of Directors PORTLAND, Ore. (BUSINESS WIRE)
Marvin S. Hausman MD Rejoins OXIS International Inc. Board of Directors PORTLAND, Ore. (BUSINESS WIRE) Aug. 23, 2004 OXIS International, Inc. (OTCBB:OXIS) announced today that Marvin S. Hausman MD has rejoined the Board of Directors. Dr. Hausman previously served on the OXIS bo
Read more →Competitive Position
How GTBP ranks across every disease it competes inCompetitive Position is a premium feature
See how GTBP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial